SWOT Analysis for Vivanza Biosciences Ltd.

Add SWOT widget to your site/app

Relative Outperformance versus Industry over 1 Month
PEG lower than Industry PEG
Relative Outperformance versus Industry over 1 Month
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Growth in Net Profit with increasing Profit Margin (QoQ)
Companies with Zero Promoter Pledge
Stock with Low PE (PE < = 10)
MACD crossed above zero line previous end of day

Relative Outperformance versus Industry over 1 Month

PEG lower than Industry PEG

Relative Outperformance versus Industry over 1 Month

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Growth in Net Profit with increasing Profit Margin (QoQ)

Companies with Zero Promoter Pledge

Stock with Low PE (PE < = 10)

MACD crossed above zero line previous end of day

Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Degrowth in Revenue and Profit
Declining Net Cash Flow : Companies not able to generate net cash
Major fall in TTM Net Profit
Fall in Quarterly Revenue and Net Profit (YoY)
Companies Increasing Debt as per Annual Report
Increasing Trend in Non-Core Income
Highest fall from 52 Week High
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Degrowth in Revenue and Profit

Declining Net Cash Flow : Companies not able to generate net cash

Major fall in TTM Net Profit

Fall in Quarterly Revenue and Net Profit (YoY)

Companies Increasing Debt as per Annual Report

Increasing Trend in Non-Core Income

Highest fall from 52 Week High

Top Losers

Stocks Underperforming their Industry Price Change in the Quarter

Big Deal (Insider and SAST) sells last month greater than 1% of total shares
Insiders sold stocks

Big Deal (Insider and SAST) sells last month greater than 1% of total shares

Insiders sold stocks

High Piotroski Score - Companies with strong financials
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks
Decline in Quarterly Net Profit with falling Profit Margin (YoY)

High Piotroski Score - Companies with strong financials

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Decline in Quarterly Net Profit with falling Profit Margin (YoY)

Vivanza Biosciences Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Vivanza Biosciences Ltd. has 8 Strengths, 10 Weaknesses, 0 Opportunities and 2 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Relative Outperformance versus Industry over 1 Month

PEG lower than Industry PEG

Relative Outperformance versus Industry over 1 Month

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Growth in Net Profit with increasing Profit Margin (QoQ)

Companies with Zero Promoter Pledge

Stock with Low PE (PE < = 10)

MACD crossed above zero line previous end of day

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Degrowth in Revenue and Profit

Declining Net Cash Flow : Companies not able to generate net cash

Major fall in TTM Net Profit

Fall in Quarterly Revenue and Net Profit (YoY)

Companies Increasing Debt as per Annual Report

Increasing Trend in Non-Core Income

Highest fall from 52 Week High

Top Losers

Stocks Underperforming their Industry Price Change in the Quarter

Big Deal (Insider and SAST) sells last month greater than 1% of total shares

Insiders sold stocks

High Piotroski Score - Companies with strong financials

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Decline in Quarterly Net Profit with falling Profit Margin (YoY)